Crescent Biopharma Quarterly Cash Flow Statement
NASDAQ: CBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.91+0.79 (+5.59%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Crescent Biopharma free cash flow
In the quarter ended Jun 30, 2026, Crescent Biopharma generated -$19.5 million of operating cash flow and spent $13,000 on capital expenditures. That left free cash flow of -$19.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Crescent Biopharma cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -24.84M | -23.28M | -23.30M | -24.61M | -21.79M | -2.34M | -7.22M | -9.82M | -10.10M | -10.74M | -9.08M | -9.20M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 66.00K | 64.00K | 54.00K | 28.00K | 2.00K | 0 | 0 | 8.13K | 12.42K | 14.62K | 23.30K | 42.75K |
| Stock-Based Compensation | 3.96M | 4.11M | 4.75M | 1.99M | 5.34M | 1.23M | 1.13M | 1.14M | 1.21M | 1.19M | 908.37K | 887.84K |
| Change in Working Capital | -339.00K | 17.02M | 37.00K | 47.00K | 78.00K | -3.09M | 1.65M | 369.48K | -241.35K | -1.42M | 1.06M | -381.18K |
| Operating Cash Flow | -19.46M | -8.94M | -26.74M | -17.54M | -16.40M | -10.85M | -6.27M | -7.99M | -8.89M | -10.51M | -7.61M | -8.68M |
| Capital Expenditures | -13.00K | -147.00K | -193.00K | -586.00K | -140.00K | 0 | 0 | 0 | -2.53K | -7.44K | -801 | -7.87K |
| Investing Cash Flow | 1.76M | -8.15M | -72.19M | -586.00K | -140.00K | 0 | 0 | 0 | -2.53K | -7.44K | -801 | -7.87K |
| Debt Issued | — | — | — | — | — | — | 37.48M | — | — | — | — | — |
| Financing Cash Flow | 136.00K | -6.95M | 178.86M | -1.25M | 146.86M | -1.49M | 41.03M | 0 | 500 | 4.90K | 999 | 61.62K |
| Net Change in Cash | -17.57M | -24.03M | 79.93M | -19.38M | 130.32M | -12.34M | 34.77M | -7.99M | -8.90M | -10.51M | -7.61M | -8.63M |
| Free Cash Flow | -19.48M | -9.08M | -26.93M | -18.13M | -16.54M | -10.85M | -6.27M | -7.99M | -8.90M | -10.52M | -7.62M | -8.69M |
This table shows 12 quarterly periods of Crescent Biopharma's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CBIO's reporting calendar. What is a cash flow statement?